Drug Search Results
More Filters [+]

Elacytarabine

Alternative Names: elacytarabine, cp-4055, cp4055, cp 4055
Latest Update: 2013-09-27
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Global Transcription Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Clavis Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Elacytarabine

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Leukemia|Acute Myeloid Leukemia

Phase 2: Chronic Myeloid Leukemia|Myelodysplastic Syndrome|Acute Myeloid Leukemia|Chronic Lymphoid Leukemia|Melanoma|Colorectal Cancer|Ovarian Cancer|Leukemia

Phase 1: Healthy Volunteers|Leukemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2006-7041-83/hah

N/A

Not yet recruiting

Pain Unspecified

2021-12-31

2008-008518-38

P2

Terminated

Leukemia

2013-05-07

CP4055-205

P2

Completed

Acute Myeloid Leukemia

2013-05-01

CP-4055

P1

Completed

Leukemia

2013-05-01

Recent News Events

Date

Type

Title